https://www.einpresswire.com/article/522824164/hagens-berman-national-trial-attorneys-encourages-vaxart-vxrt-investors-with-significant-losses-and-persons-who-may-assist-firm-s-investigation-of
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Vaxart (VXRT) Investors with Significant Losses...
Jul 29, 2020 - Hagens Berman urges Vaxart, Inc. (NASDAQ: VXRT) investors who have suffered significant losses to submit their losses now. Hagens Berman also encourages persons
hagens bermantrial attorneys
https://menafn.com/1111058514/Vaxart-To-Host-Stockholder-Fireside-Chat-On-May-8-At-430-PM-ET
Vaxart To Host Stockholder Fireside Chat On May 8 At 4:30 P.M. ET
Vaxart To Host Stockholder Fireside Chat On May 8 At 4:30 P.M. ET. Company to report first quarter 2026 financial results on May 7 SOUTH SAN FRANCISCO, Calif.,...
https://vaxartsecuritieslitigation.com/
Vaxart Securities Litigation
If You Purchased Vaxart, Inc. Common Stock or Options Between June 25, 2020, Through July 24, 2020, You May Be Part of This Litigation.
vaxartsecuritieslitigation
https://www.biospace.com/vaxart-to-host-second-quarter-2024-business-update-and-financial-results-conference-call-on-august-8
Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August...
https://www.biospace.com/press-releases/vaxart-to-present-at-the-citizens-life-sciences-conference
Vaxart to Present at the Citizens Life Sciences Conference - BioSpace
the citizenslife sciencesvaxartpresentconference
https://www.prnewswire.com/news-releases/kindred-biosciences-announces-covid-19-vaccine-manufacturing-agreement-with-vaxart-301062265.html
Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
/PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has entered into an...
covid 19 vaccinekindredbiosciencesannouncesmanufacturing
https://www.biospace.com/press-releases/vaxart-appoints-jeroen-grasman-as-chief-financial-officer
Vaxart Appoints Jeroen Grasman as Chief Financial Officer - BioSpace
chief financial officervaxartappointsjeroen
https://www.macrotrends.net/stocks/charts/VXRT/vaxart,-inc/roe
VAXART, INC ROE 2012-2026 | VXRT | MacroTrends
Current and historical return on equity (ROE) values for VAXART, INC (VXRT) over the last 10 years. Return on equity can be defined as the amount of net income...
vaxartincroe20122026
https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-microvision-naked-brand-vaxart-zomedica-or-neptune-wellness-solutions-301279235.html
Thinking about buying stock in Microvision, Naked Brand, Vaxart, Zomedica, or Neptune Wellness...
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MVIS, NAKD, VXRT, ZOM, and NEPT. To see how InvestorsObserver's proprietary scoring...
https://www.fool.com/investing/2020/10/13/why-vaxart-stock-is-jumping-today/
Why Vaxart Stock Is Jumping Today | The Motley Fool
Oct 13, 2020 - The biotech has begun a phase 1 study of its oral COVID-19 vaccine candidate.
the motleyvaxartstockjumpingtoday
https://www.fiercebiotech.com/biotech/vaxart-lays-10-staff-after-hhs-unexpectedly-demands-halt-covid-vaccine-trial
Vaxart lays off 10% of staff after HHS unexpectedly demands halt to COVID vaccine trial | Fierce...
Mar 21, 2025 - Vaxart has laid off 10% of its staff after the U.S.
https://robinhood.com/us/en/stocks/VXRT/
Vaxart: VXRT Stock Price Quote & News | Robinhood
You can watch VXRT and buy and sell other stocks, ETFs, and their options commission-free on Robinhood. Change the date range, see whether others are buying or...
stock pricevaxartquotenewsrobinhood
https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-motus-gi-aurinia-pharmaceuticals-aptose-biosciences-vaxart-or-atossa-therapeutics-301281193.html
Thinking about buying stock in Motus GI, Aurinia Pharmaceuticals, Aptose Biosciences, Vaxart, or...
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MOTS, AUPH, APTO, VXRT, and ATOS. To see how InvestorsObserver's proprietary scoring...
https://www.biospace.com/vaxart-announces-positive-preliminary-data-from-phase-1-clinical-trial-evaluating-its-oral-covid-19-tablet-vaccine-candidate
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19...
Feb 3, 2021 - Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines administered by tablet, today announced preliminary data from its...
https://www.fool.com/investing/2021/03/05/can-this-1-element-keep-vaxart-in-the-coronavirus/
Can This 1 Element Keep Vaxart in the Coronavirus Vaccine Race? | The Motley Fool
Mar 5, 2021 - Vaxart's trial data disappointed -- but one bright spot could turn things around.
https://www.fool.com/investing/2021/06/15/why-covid-vaccine-stocks-dynavax-novavax-and-vaxar/
Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today | The Motley Fool
Jun 15, 2021 - The declines appear to be caused simply by volatility that's common with small biotech stocks.
https://www.acsh.org/news/2019/04/17/hurdle-no-hurl-vaxart-starts-phase-ib-norovirus-vaccine-trials-13965
Hurdle But No Hurl: Vaxart Starts Phase Ib Norovirus Vaccine Trials | American Council on Science...
Vaxart Inc., a San Francisco based vaccine biotech, just announced that it will begin dosing subjects in a Phase 1b study company's bivalent oral experimental...
https://www.biospace.com/vaxart-provides-business-update-and-reports-second-quarter-2023-financial-results
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results - BioSpace
Aug 3, 2023 - Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the second quarter of 2023.
business update
https://www.biospace.com/vaxart-announces-positive-safety-and-immunogenicity-results-for-its-oral-norovirus-vaccine-in-a-phase-1b-clinical-study
Vaxart Announces Positive Safety and Immunogenicity Results for Its Oral Norovirus Vaccine in A...
Oct 31, 2017 - The norovirus tablet vaccine was generally well tolerated in all subjects. Adverse events (AEs) were mostly mild in severity with headache as the most frequent...